

AUTHOR INDEX

- | | | |
|---|---|--|
| <p>Abromovitz, L., 60
 Aitken, T.J., 97, 99</p> <p>Baysinger, M., 78
 Berman, S.J., 57
 Betcher, D.L., 31, 87, 136, 192
 Bowman, J., 50
 Bryant, J., 3, 49
 Burnbaum, N., 192
 Burnham, N., 31, 87, 136</p> <p>Clarke, D., 56
 Clarke-Steffen, L., 52
 Cohen, D.G., 68, 69
 Connaughty, S., 56
 Cook, K., 56</p> <p>Dagesse, J., 50
 Davies, B., 56
 DeZorzi, P., 63
 Donohoe, M., 54
 Driscoll, J.W., 80
 Dulczak, S., 57
 Duncan, J., 76
 Duncan, K., 50
 Dunn, J., 79</p> <p>Emery, J.E., 131</p> <p>Fairclough, D., 54
 Feeg, V.D., 52
 Fergusson, J.H., 51
 Fish, L., 65
 Fletcher, J.A., 64
 Fochtman, D., 1, 43, 145</p> | <p>Foley, G., 66
 Foote, A., 17
 Freiberger, D., 3
 Gleason-Morgan, D., 139
 Golden, D., 60
 Gonzalez, L., 194
 Guinan, E., 49</p> <p>Hammer, E., 67
 Hanigan, M.J., 71, 110
 Heiney, S., 76
 Heiney, S.P., 78
 Hinds, P., 54
 Hinds, P.S., 84
 Hobbie, W., 55, 70
 Hockenberry-Eaton, M., 132
 Holcombe, J., 17
 Hollen, P., 55
 Holt, C., 67
 Hornberger, L., 60</p> <p>Keegan-Wells, D., 159
 Klein, E.R., 170</p> <p>LaVally, B., 60
 Li, F.P., 64
 Luciano, C.A., 48</p> <p>Mackenzie, B., 56
 Marino, B., 3
 Martin, G.A., 54
 McCormick, J., 56</p> <p>O'Loane, M., 56
 Overbaugh, K.A., 8</p> | <p>Patterson, K.L., 119
 Pauckett, P., 54
 Payne, K., 54
 Perin, G., 57
 Phipps, S., 54
 Piazza, D., 17</p> <p>Quargnenti, A.G., 84</p> <p>Rasco, C., 33
 Reid, D., 194</p> <p>Sawin, K., 8
 Servetar, E.M., 25
 Sievers, T.D., 53
 Smith, S., 69
 Sonis, A., 70
 Spector, R.E., 66
 Stewart, J.L., 159
 Stutzer, C., 56</p> <p>Test, J., 60
 Thompson, J.R., 67</p> <p>Wagner, D., 61
 Walker, C.L., 29
 Walsh, B.A., 146
 Walter, G.A., 110
 Weekes, D.P., 60, 187
 Wentz, T.J., 84
 Williams, H.A., 77, 180
 Wright, P., 17</p> |
|---|---|--|

SUBJECT INDEX

- | | |
|--|---|
| <p>Acetaminophen, 125, 127
 Addition, pain medication and, 126-127
 Adolescent
 decision making and risk taking characteristics of, 55-56
 education intervention program for, 78-79
 patient-controlled analgesia for, 68
 self-esteem and, 8-16
 support group for, 76
 symptom distress in, 84-86
 Amikacin, 150
 Amikin, 150
 Aminoglycoside, 150
 Amphotericin B, 150, 194-195
 Analgesia, patient-controlled, 68</p> | <p>Ancobon, 150
 Anthropometric measurement, 113-114
 Antibiotic, 150
 Antidepressant, 126
 Antiemetic, 103-104
 Antifungal agent, 150
 Antihistamine, as antiemetic, 103-104
 Antiseptic, central venous line dressing change and, 3-7
 Anxiety, music therapy and, 33-34
 APON, See Association of Pediatric Oncology Nurses
 Aspirin, 127
 Association of Pediatric Oncology Nurses Annual Conference, 1991, 46-80
 bone marrow transplantation overview, 49</p> |
|--|---|

Annual Conference (*Continued*)

- cancer family syndrome, 64
- case study model for pediatric oncology nursing course, 61-62
- chemotherapy certification program, 63
- chemotherapy update, 65
- chromosomal abnormalities, 64-65
- classroom teacher with students undergoing cancer treatment, 60-61
- conscious sedation with midazolam, 53-54
- cultural responses to illness, 66-67
- developmental outcomes of childhood cancer, 52
- educational trajectory approach, 78-79
- family transition in childhood cancer, 52-53
- grief workshop for pediatric oncology nurses, 54-55
- historical perspective of pediatric oncology nursing, 51
- home movies for school re-entry, 69
- long-term endocrine effects of cancer therapy, 70
- New England Medical Center Floating Hospital for Infants and Children, 50-51
- nurse manager strategies, 48
- nursing care to terminally ill children, 56-57
- Nursing Research Committee, 57-59
- open communication about end-stage disease, 57
- oral complications of cancer treatment, 70
- patient-controlled analgesia, 68
- pediatric brain tumor, 60, 67-68
- peer review tool, 79
- risk taking and decision making in adolescent cancer survivors, 55-56
- self-care for nurses, 80
- social support for black parents versus white parents, 77-78
- support groups, 76
- unrelated bone marrow transplantation, 71-75
- writing for publication, 66

Bactrim, 150

Barbiturate, 123

Bed, 156

Benzodiazepine, 104, 123

Betadine, for central venous line dressing change, infection and, 3-7

Bone marrow transplantation, 49
unrelated, 71-75

Brain tumor

effects on cognition and learning, 67-68

nursing challenges in, 60

Breathing exercise, 124

Broviac catheter, 159

Camptothecin, semisynthetic analog of, 31-32

Candida, 147, 148, 150, 153

Case study model, for pediatric oncology nursing course, 61-62

Catheter, *See also* Venous access device(s)

Broviac, 159

central

peripherally inserted, 161, 163-164

tunneled, 160-162

Catheter (*Continued*)

- infection related to, dressing change and, 3-7
- Twiddler's syndrome and, 25-28

2-CDA, *See* Chlorodeoxyadenosine

Ceftazidime, 150

Central venous catheter, complications of, 81-83

Cephalosporin, 150

Certification program, 61-63

Chemotherapy

certification program for administration of, 61-63

extravasation in, 65

handling of agents for, 65

Chloral hydrate, 123

Chlorhexidine, *See also* Hibiclens

in stomatitis, 100

2-Chlorodeoxyadenosine (2-CDA), 192-193

Choline magnesium trisalicylate, 127

Chromosome abnormality, cancer and, 64-65

Clavulanic acid, 150

Cognition, brain tumor and, 67-68

Colony-stimulating factor, 152

Communication, end-stage disease and, 57

Constipation, cancer therapy and, 105-106

Corticosteroid, 104, 126-127

Cultural factor, in response to illness, 66-67

Decision making, adolescent cancer survivor and, 55-56

DEN, *See* Food and Drug Administration, Device Experience Network

Development, in Neuman Systems Model, 21-22

Dexamethasone, 104

Diarrhea, 106-107

Diazepam, 123

Diflucan, 150

Distraction, during medical procedure, 124

Dressing change, catheter-related infection and, 3-7

Education

adolescent undergoing cancer treatment and, 78-79

intervention for teacher and, 60-61

End-stage disease, nursing experiences and, 56-57

Endocrine system, cancer therapy effect on, 70

Environment, Neuman Systems Model and, 19, 21

Family

human immunodeficiency virus handbook for, 139-140

risk of cancer in, 64-65

support for, 180-186

FDA, *See* Food and Drug Administration

Fentanyl, 123

Fiber, dietary, 105

Fluconazole, 150

Flucytosine, 150

Fludara, 87-89

Fludarabine phosphate, 87-89

Fluid and electrolyte balance, cancer therapy and, 102-105

Fluorouracil, 150

Food and Drug Administration

Central Venous Catheter Working Group, 81-83

Device Experience Network, 82-83

- Fortaz, 150
Fungal infection, 150. *See also Candida*
Fungizone, 150
Future expectations, of adolescent survivor of childhood cancer, 8-16
- Gastrointestinal disorder, cancer therapy and, 99-109
Gauze, in central venous line dressing change, infection and, 3-7
Genetics, cancer and, 64-65
Gluconeogenesis, 111
Graft-versus-host disease, diarrhea and, 107
Grief workshop, for pediatric oncology nurse, 54-55
- Halothane, 123
Hibiclens, *See also* Chlorhexidine
 in central venous line dressing change, infection and, 3-7
Histiocytosis, Langerhans' cell, Twiddler's syndrome and, 25-28
Home movie, for school re-entry, 69
Human immunodeficiency virus, family handbook for, 139-140
Hycamtamine, 31-32
Hypnosis, 124
Hypoproteinemia, 111
- Ibuprofen, 127
Imagery, 124
Imidazole, 150
Infection
 acute lymphocytic leukemia and, 146-158
 central venous line dressing change and, 3-7
 fungal, 150. *See also Candida*
Invasive procedure
 pain and, 53-54, 122-125. *See also* Pain
 premedication for, 170-179
- Ketamine, 123
Ketoconazole, 150
- Langerhans' cell histiocytosis, Twiddler's syndrome and, 25-28
Learning, brain tumor and, 67-68
Leukemia
 lymphocytic, acute, 146-158
 Neuman Systems Model in nursing care for, 17-24
Lidocaine, 123
Lorazepam, 104, 123
Lumbar puncture, music therapy during, 33-34
- Malnutrition, 110-118
Marijuana, 104
Mattress, 156
Media Review, 35-38, 90-93, 141-144, 196-198
Mentorship, 132-135
Meperidine, 123
Metoclopramide, 104
Midazolam, 53-54, 123
 for outpatient sedation, 136-138
Morphine sulfate, 123
Motrin, 127
- Mouthwash, 101
Multidisciplinary health care delivery system, 50-51
Music therapy, during lumbar puncture, 33-34
Mycostatin, in stomatitis, 100
- Naprosyn, 127
Naproxen, 127
Nausea, cancer therapy and, 102-105
Neuman Systems Model
 catheter related infection and, 4-5
 overview of, 17-24
Neutropenia
 febrile, 149
 stomatitis and, 99
New England Medical Center Floating Hospital for Infants and Children, 50-51
Nitrous oxide, 123
Nizoral, 150
Nonsteroidal anti-inflammatory drug, 125
Nurse manager, 48
Nursing diagnosis, in Neuman Systems Model, 22-24
Nursing Research Committee, 57-59
Nutrition, 110-118
Nystatin, 150
- Opioid, 123, 125-126, 127
Oral complications, of cancer treatment, 70
Oral hygiene, 101
- p53 tumor suppressor gene, 64
Pain, 119-130
 addiction considerations in treatment for, 126-127
 assessment of, 119
 behavior scales for, 120, 121
 disease-related, 125-129
 epidemiology of, 119
 midazolam for, 53-54
 pharmacological management of, 123
 physiological manifestations of, 120
 self-report measures for, 120, 121
 treatment of, 120-122
 treatment-related, 53-54, 122-125
Parent
 of adolescent survivor of childhood cancer, 8-16
 black, support for, 77-78
 health professional as, 184-185
 support group for, 76-78
Peer review tool, 79
Pentothiazine, 103
Pentobarbital, 123
Pneumocystis carinii, 146
Procainamide derivative, 104
Prostaglandin, 104
Protein, metabolism of, 111
Providone-iodine, in central venous line dressing change, infection and, 3-7
Psychological factor, in Neuman Systems Model, 21
Psychology, nutrition and, 112
Psychosocial responses, of family, 52-53
Psychostimulant, 126
Publication, writing for, 66

- Relaxation training, 124
- Research, 132-135
- human response in, 189-190
 - patterns and trends in, 188
 - personal experience as source of, 187-188
 - problem identification in, 187-191
 - theoretical frameworks for, 188
- Rifampin, 150
- Risk taking, adolescent cancer survivor and, 55-56
- Salicylate, 125
- School
- home movies for re-entry to, 69
 - intervention in, 78-79
 - student undergoing cancer treatment and, 60-61
- Self-esteem, adolescent survivor of childhood cancer and, 8-16
- Self-talk, positive, 124
- Sepsis, catheter-related, dressing change and, 3-7
- Serotonin antagonists, 104
- SK&F 104864, *See* Topotecan
- Skin care, 151, 155-157
- catheter-related infection and, 4
- Social support
- for black parents, 77-78
 - for family, 180-186
- Staff, support group for, 76
- Steroid, 104
- Stomatitis, cancer therapy and, 99-102
- Stress, pediatric oncology nurse and, 54-55
- Student, effect of cancer treatment on, 60-61
- Sulfonamide, 150
- Support group
- for adolescent, 76
 - for parent, 76-78
- Supportive care, nursing, 97-98
- Survivor, adolescent, self-esteem and, 8-16
- Symptom distress, in adolescent, 84-86
- Teacher, with students undergoing cancer treatment, 60-61
- Tegaderm, in central venous line dressing change, infection and, 3-7
- Terminal illness, nursing experiences with, 56-57
- Ticarcillin, 150
- Timentin, 150
- Tolerance, drug, 126
- Topotecan, 31-32
- Trisate, 127
- Twiddler's syndrome, case report of, 25-28
- Ulcer, skin, 155-157
- Vancocin, 150
- Vancomycin, 150
- Venous access device(s), 159-169, *See also* Catheter
- comparison of, 161
 - complications associated with, 164-167
 - developmental considerations for, 167
 - history of, 159
 - implanted infusion port as, 161, 162-163
 - patient and parent education for, 167-168
 - peripherally inserted central catheter as, 161, 163-164
 - tunneled central catheter as, 160-162
 - types of, 160-164
- Vomiting, cancer therapy and, 102-105
- WHO, *See* World Health Organization
- World Health Organization, ladder approach to pain, 125
- Wound care, 155-157
- Writing, for publication, 66

